Trial Now Recruiting: Dabrafenib and/or Trametinib Rollover Study (NCT03340506)
WHY IT MATTERS
This rollover study allows patients whose cancers are responding well to dabrafenib and/or trametinib to continue access to these drugs after their original trial ends, rather than losing treatment.
This is a continuation study for patients who are already taking the cancer drugs dabrafenib and/or trametinib and have done well on them. If your doctor thinks you're still benefiting from these medications after your original trial ends, you may be able to keep taking them through this new study. The study is looking for about 100 patients with various types of cancer including melanoma, lung cancer, and brain tumors.
NCT ID: NCT03340506 Status: RECRUITING Conditions: Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma Phase: PHASE4 Enrollment: 100 Sponsor: Novartis Pharmaceuticals Summary: This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
YOU CAN ACT ON THIS
If you are currently in a Novartis or GSK-sponsored dabrafenib or trametinib study and your cancer is responding well, ask your study doctor immediately whether you qualify for this rollover study (NCT03340506) to continue your treatment.